InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2026-02-05 | Tim Moore(R-NC14) | house | Purchase | $1,001 - $15,000 |
| 2025-12-18 | Tim Moore(R-NC14) | house | Purchase | $1,001 - $15,000 |
| 2025-11-07 | Tim Moore(R-NC14) | house | Purchase | $1,001 - $15,000 |
| 2025-10-29 | Tim Moore(R-NC14) | house | Purchase | $15,001 - $50,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Depreciation | $0-100.0% | $7K-55.4% | $15K-41.3% | $26K |
| Research and development | $9.4M-10.5% | $10.5M-40.2% | $17.6M+53.1% | $11.5M |
| General and administrative | $6.1M-42.7% | $10.6M-20.8% | $13.4M+9.2% | $12.3M |
| Total operating expenses | $15.5M-26.7% | $21.2M | — | — |
| Operating loss | -$15.5M+26.7% | -$21.2M+31.8% | -$31.1M-30.3% | -$23.8M |
| Other income | $27K-57.7% | $64K | — | — |
| Other financing costs | -$740K | $0 | — | — |
| Realized and unrealized loss | -$299+47.5% | -$570 | — | — |
| Net loss | -$16.2M+23.1% | -$21.1M+31.6% | -$30.9M-30.0% | -$23.7M |
| Deemed dividend related to warrant modification | $0+100.0% | -$277K | $0 | — |
| Net loss attributable to common stockholders | -$16.2M+24.1% | -$21.4M+30.7% | -$30.9M | — |
| Net loss per share applicable to common stockholders — basic and diluted (in dollars per share) | -$17.4+93.5% | -$266.89-1083.0% | -$22.56 | — |
| Weighted average number of common shares — basic and diluted (in shares) | $933K+1063.9% | $80K-94.1% | $1.4M+14.1% | $1.2M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy